Clinical trial
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
NCT00086034 · Pharmacyclics LLC., Industry · Completed
Key facts
| NCT number | NCT00086034 |
|---|---|
| Title | Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma |
| Official title | Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Motexafin gadolinium |
| Enrollment | 35 |
| First posted | Jun 23, 2004 |
| Last update posted | May 15, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: